2024-02-18 23:32:12 ET
Summary
- Royalty Pharma delivered outstanding results in 2023 and deployed capital in key value-enhancing transactions.
- The company increased its dividend per share by 5% and reported adjusted cash receipts that exceeded internal expectations.
- Royalty Pharma provided new full-year 2024 guidance. Still no news on Vertex. That said, we believe the company offers an attractive entry point.
Royalty Pharma plc ( RPRX ) released its Q4 results yesterday. The company delivered outstanding results in 2023 and deployed capital in key value-enhancing transactions for a total consideration of $4 billion....
Read the full article on Seeking Alpha
For further details see:
Royalty Pharma: Solid Operational Performance